[Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs].

Q4 Medicine

Nederlands tijdschrift voor geneeskunde Pub Date : 2025-02-25

Haras Mhmud, Odette A M Tigchelaar-Besling, Jeroen P Vermeulen, Frank D Verbraak, Daniel Barthelmes, Mark Gillies, Theodorus L Ponsioen, Caroline C W Klaver

{"title":"[Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs].","authors":"Haras Mhmud, Odette A M Tigchelaar-Besling, Jeroen P Vermeulen, Frank D Verbraak, Daniel Barthelmes, Mark Gillies, Theodorus L Ponsioen, Caroline C W Klaver","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To study the long-term outcomes of anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) in the Netherlands, where off-label bevacizumab is used as the first choice, compared to countries that typically use ranibizumab or aflibercept.Design: Prospective real-world observational study.Methods: A total of 1,617 Dutch eyes were compared with 8,667 eyes from a reference group derived from 13 socio-economically comparable countries. The primary outcome was the mean visual acuity (VA) measured at annual intervals up to 60 months. Secondary outcomes included injection frequency and the rate of switching to an alternative injection type.Results: Dutch eyes exhibited higher VA, received two additional injections annually and switched to alternative treatments more frequently (65.2% vs. 50.1%) and sooner (14.6 months vs. 17.9 months).Conclusion: Dutch patients achieved higher VA after 60 months compared to the reference group. This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type.","PeriodicalId":18903,"journal":{"name":"Nederlands tijdschrift voor geneeskunde","volume":"169 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nederlands tijdschrift voor geneeskunde","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the long-term outcomes of anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) in the Netherlands, where off-label bevacizumab is used as the first choice, compared to countries that typically use ranibizumab or aflibercept.

Design: Prospective real-world observational study.

Methods: A total of 1,617 Dutch eyes were compared with 8,667 eyes from a reference group derived from 13 socio-economically comparable countries. The primary outcome was the mean visual acuity (VA) measured at annual intervals up to 60 months. Secondary outcomes included injection frequency and the rate of switching to an alternative injection type.

Results: Dutch eyes exhibited higher VA, received two additional injections annually and switched to alternative treatments more frequently (65.2% vs. 50.1%) and sooner (14.6 months vs. 17.9 months).

Conclusion: Dutch patients achieved higher VA after 60 months compared to the reference group. This higher VA was associated with a greater number of injections and a tendency to switch to a more expensive registered anti-VEGF injection type.

本刊更多论文

贝伐单抗治疗老年性黄斑变性：注射更多，视力更好，成本更低。

目的：研究荷兰抗vegf治疗新生血管性年龄相关性黄斑变性（nAMD）的长期结果，在荷兰，非标签贝伐单抗被用作首选，与通常使用雷尼单抗或阿非利塞普的国家相比。设计：前瞻性现实世界观察研究。方法：将1617只荷兰人的眼睛与来自13个社会经济可比国家的8667只参考组的眼睛进行比较。主要结果是平均视力（VA），每隔60个月测量一次。次要结局包括注射频率和切换到另一种注射类型的比率。结果：荷兰人的眼睛表现出更高的VA，每年接受两次额外注射，更频繁（65.2%对50.1%）和更早（14.6个月对17.9个月）切换到替代治疗。结论：与对照组相比，荷兰患者在60个月后获得更高的VA。较高的VA与更多的注射次数和转向更昂贵的注册抗vegf注射类型的趋势有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nederlands tijdschrift voor geneeskunde Medicine-Medicine (all)

CiteScore

0.30

自引率

0.00%

发文量

302

期刊介绍： Het NTVG staat bekend als hét wetenschappelijke algemene medische tijdschrift. De lange historie en de degelijkheid maken het tijdschrift tot een bolwerk van medische wetenschap in druk. Ook door de goede leesbaarheid draagt het tijdschrift bij aan de voortdurende dialoog over de geneeskunde.